Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $723.05 | 7 | 80.9% |
| Education | $170.94 | 2 | 19.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novocure Inc. | $125.00 | 1 | $0 (2019) |
| Pharmacyclics LLC, An AbbVie Company | $125.00 | 1 | $0 (2018) |
| Celgene Corporation | $124.29 | 1 | $0 (2019) |
| Novo Nordisk Inc | $121.60 | 1 | $0 (2019) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $112.06 | 1 | $0 (2017) |
| Daiichi Sankyo Inc. | $100.00 | 1 | $0 (2017) |
| Seagen Inc. | $90.95 | 1 | $0 (2023) |
| Janssen Biotech, Inc. | $79.99 | 1 | $0 (2019) |
| Genentech USA, Inc. | $15.10 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15.10 | 1 | Genentech USA, Inc. ($15.10) |
| 2023 | $90.95 | 1 | Seagen Inc. ($90.95) |
| 2019 | $450.88 | 4 | Novocure Inc. ($125.00) |
| 2018 | $125.00 | 1 | Pharmacyclics LLC, An AbbVie Company ($125.00) |
| 2017 | $212.06 | 2 | NOVARTIS PHARMACEUTICALS CORPORATION ($112.06) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/02/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $15.10 | General |
| Category: BioOncology | ||||||
| 06/21/2023 | Seagen Inc. | — | Education | In-kind items and services | $90.95 | General |
| 12/19/2019 | Janssen Biotech, Inc. | Erleada (Drug) | Education | In-kind items and services | $79.99 | General |
| Category: Oncology | ||||||
| 05/09/2019 | Novocure Inc. | Oncology (Device) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Optune | ||||||
| 04/25/2019 | Novo Nordisk Inc | NovoSeven RT (Drug) | Food and Beverage | In-kind items and services | $121.60 | General |
| Category: Hemophilia | ||||||
| 02/13/2019 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $124.29 | General |
| Category: Hematology / Oncology | ||||||
| 09/20/2018 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 11/02/2017 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: Anemia | ||||||
| 08/09/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Food and Beverage | In-kind items and services | $112.06 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 361 | 580 | $259,066 | $57,673 |
| 2022 | 6 | 320 | 477 | $202,700 | $48,825 |
| 2021 | 7 | 391 | 556 | $241,823 | $59,299 |
| 2020 | 9 | 263 | 380 | $149,103 | $33,015 |
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 129 | 293 | $134,901 | $31,172 | 23.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 101 | 134 | $45,696 | $9,133 | 20.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 62 | 62 | $39,350 | $7,722 | 19.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 38 | 39 | $23,515 | $5,312 | 22.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 37 | $12,213 | $3,395 | 27.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 15 | $3,391 | $939.00 | 27.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 101 | 195 | $85,215 | $21,624 | 25.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 54 | 60 | $37,200 | $9,361 | 25.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 93 | 135 | $43,740 | $9,262 | 21.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 33 | 33 | $20,691 | $4,536 | 21.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 27 | 40 | $12,760 | $3,250 | 25.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 14 | $3,094 | $790.88 | 25.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 65 | 154 | $67,298 | $17,788 | 26.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 76 | 76 | $47,652 | $10,933 | 22.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 49 | 55 | $34,100 | $8,647 | 25.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 71 | 95 | $30,780 | $7,283 | 23.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 27 | 45 | $14,355 | $3,685 | 25.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 19 | 34 | $14,858 | $3,272 | 22.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 36 | 49 | $10,829 | $2,858 | 26.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 17 | 17 | $10,659 | $2,241 | 21.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 13 | 13 | $5,460 | $1,425 | 26.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 18 | 18 | $5,832 | $1,168 | 20.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 34 | 96 | $41,952 | $8,632 | 20.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 39 | 40 | $16,800 | $4,514 | 26.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 30 | 56 | $18,144 | $3,479 | 19.2% |
About Dr. Daniel Anscher, M.D
Dr. Daniel Anscher, M.D is a Hematology healthcare provider based in Orlando, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/21/2013. The National Provider Identifier (NPI) number assigned to this provider is 1174865745.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Anscher, M.D has received a total of $893.99 in payments from pharmaceutical and medical device companies, with $15.10 received in 2024. These payments were reported across 9 transactions from 9 companies. The most common payment nature is "Food and Beverage" ($723.05).
As a Medicare-enrolled provider, Anscher has provided services to 1,335 Medicare beneficiaries, totaling 1,993 services with total Medicare billing of $198,811. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Practice Information
- Specialty Hematology
- Location Orlando, FL
- Active Since 03/21/2013
- Last Updated 06/20/2019
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1174865745
Products in Payments
- Imbruvica (Drug) $125.00
- Oncology (Device) $125.00
- Revlimid (Drug) $124.29
- NovoSeven RT (Drug) $121.60
- INJECTAFER (Drug) $100.00
- Erleada (Drug) $79.99
- Columvi (Biological) $15.10
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Orlando
Raji Shameem, M.d, M.D
Hematology — Payments: $668,680
Cesar Perez Batista, M.d, M.D
Hematology — Payments: $119,170
Chung Che Chang, Md, MD
Hematology — Payments: $30,072
Dr. Geethanjali Akula, M.d, M.D
Hematology — Payments: $29,361
Dr. Jacob Barish, M.d, M.D
Hematology — Payments: $3,952
Abhishek Chilkulwar, Md, MD
Hematology — Payments: $1,459